Vanguard Group Inc Eye Point Pharmaceuticals, Inc. Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
A detailed history of Vanguard Group Inc transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,774,454 shares of EYPT stock, worth $33.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,774,454
Previous 2,396,228
15.78%
Holding current value
$33.5 Million
Previous $49.5 Million
51.27%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding EYPT
# of Institutions
158Shares Held
57.4MCall Options Held
224KPut Options Held
1.41M-
Cormorant Asset Management, LP Boston, MA8.33MShares$101 Million5.57% of portfolio
-
Suvretta Capital Management, LLC New York, NY5.18MShares$62.5 Million1.88% of portfolio
-
Black Rock Inc. New York, NY3.76MShares$45.5 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA3.65MShares$44.1 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.59MShares$43.4 Million0.06% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $412M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...